Mark Beards

Mark Beards is Interim CEO of Santero Therapeutics, developing first-in-class RSH enzyme inhibitors for treatment-refractory infections. Previously CEO of UTILITY Therapeutics (pivmecillinam US approval), he has raised over $40 million in biotech funding, and currently chairs AMPLY Discovery, an AI Drug Discovery company. He holds an MA from Oxford and was formerly at GSK, Goldman Sachs and McKinsey.